Preliminary Findings suggest Jatcorps (ASX:JAT) supplements effective against Omicron

• Preliminary data suggests Jatcorp’s (JAT) supplements could be effective against the Omicron variant of COVID-19
• The Royal Melbourne Institute of Technology assessed JAT’s Jinvigorate Platinum and Moroka Platinum products ability to enhance immune function and antiviral activity
• While clinical trials are required to make specific health claims, the findings suggest “high binding” effectiveness against the omicron variant
• On the back of the RMIT findings, JAT and Pinnacle Laboratories co-brand CocoSoul Moroka will release five more drink products in the coming months
• Shares closed 5 per cent higher at 2.1 cents

Preliminary data suggests Jatcorp’s (JAT) supplements could be effective against the Omicron variant of COVID-19.

The products include a mixture of formulated milk powders and supplementary foods which were developed with the University of Sydney.

From September last year, the Royal Melbourne Institute of Technology was commissioned to undertake a research project ahead of clinical trials investigating the ability of JAT’s Jinvigorate Platinum and Moroka Platinum food products to promote enhanced immune function and antiviral activity.

In a computer-based study, RMIT studied anti-microbial molecules present in the food formulas to determine their potential effectiveness against SARS-CoV-2 variants.

While clinical trials to test the predictions must be completed before specific health claims are made, the findings suggest “high binding effectiveness” against the omicron variant, particularly for the lactoperoxidase enzyme product hypothiocyanite.

According to JAT, the results further reinforce the findings made previously by The University of Sydney.

In conclusion, RMIT stated that the effectiveness of milk products containing components with antiviral properties in prevention, treatment or management of COVID-19 should be further examined by in vitro and in vivo studies.

Human clinical trials are scheduled to test this hypothesis and will assess improved immune function and recovery times after contracting viruses, as well as evaluating the protection against upper respiratory tract infections.

The human subjects will be aged between 20 and 70 years of age and a total of 75 subjects will be screened and recruited.

In a co-branding agreement with Pinnacle Laboratories signed in January, the parties are developing new products under a new co-brand to be known as CocoSoul Moroka.

The products under this brand will be distributed by Saputo, one of the top-10 dairy processors in the world.

Part of this deal was based on the ability of JAT to deliver the immune support products having the antiviral properties described in The University of Sydney research.

As a result of the most recent findings in the RMIT Report, the CocoSoul Moroka products will be extended to include five drink products which are set to be released to the market by Saputo in late April or early May this year.

Shares ended trade 5 per cent higher at 2.1 cents.